SCHEMBL4581323

SCHEMBL4581323

CCN(C(=O)c1ccc(-c2cncc3ccc(C(=O)O)nc23)s1)N(C)C

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCNC P24863 8/20 0.41
CDK8 P49336 8/20 0.41
HSD17B2 P37059 3/20 0.34
ALDH1A1 P00352 2/20 0.33
HSD17B1 P14061 2/20 0.33
KDM4E B2RXH2 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
HPGD P15428 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
CSNK2A1 P68400 1/20 0.32
KDM4A O75164 1/20 0.31
MKNK1 Q9BUB5 1/20 0.30
MKNK2 Q9HBH9 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2A6 P11509 1/20 0.30
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4580596 0.92 CCNC (0.41) CCNCCDK8HSD17B2ALDH1A1HSD17B1
SCHEMBL4579213 0.82 CCNC (0.48) CCNCCDK8ALDH1A1KDM4ENPC1
SCHEMBL4580591 0.78 ACKR3 (0.43) CCNCCDK8ALDH1A1KDM4ENPC1
SCHEMBL4581316 0.78 AKT3 (0.49) CCNCCDK8ALDH1A1KDM4ENPC1
SCHEMBL4580001 0.73 CCNC (0.51) CCNCCDK8ALDH1A1KDM4ENPC1
Hydrochloric Acid SCHEMBL4581072 0.73 CCNC (0.50) CCNCCDK8ALDH1A1KDM4ENPC1
SCHEMBL4581556 0.71 CCNC (0.53) CCNCCDK8ALDH1A1KDM4ENPC1
SCHEMBL14266822 0.70 AKT3 (0.48) CCNCCDK8KDM4ENPC1RAB9A
SCHEMBL4580252 0.70 CCNC (0.48) CCNCCDK8ALDH1A1KDM4ETDP1
SCHEMBL4580254 0.68 CCNC (0.50) CCNCCDK8ALDH1A1KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080032991-A1 2, 8-disubstituted Naphthyridine Derivatives SERENEX, INC. 2008-02-07 US claimed
US-7282506-B2 2,8-disubstituted naphthyridine derivatives SERENEX, INC. (US) 2007-10-16 US claimed
US-20060030584-A1 2,8-Disubstituted naphthyridine derivatives SERENEX, INC. 2006-02-09 US claimed
US-20080032991-A1 2, 8-disubstituted Naphthyridine Derivatives SERENEX, INC. 2008-02-07 US disclosed
US-7282506-B2 2,8-disubstituted naphthyridine derivatives SERENEX, INC. (US) 2007-10-16 US disclosed
US-20060030584-A1 2,8-Disubstituted naphthyridine derivatives SERENEX, INC. 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030584-A1 2,8-Disubstituted naphthyridine derivatives CCNA1, FOXM1, CCNA2 CCNC 289/4885CDK8 516/4885HSD17B2 2172/4885
US-20080032991-A1 2, 8-disubstituted Naphthyridine Derivatives CCNA1, FOXM1, CCNA2 CCNC 289/4885CDK8 516/4885HSD17B2 2172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.